Heyman Richard A. sold $73K of ORIC (indirect holdings)
Heyman Richard A. sold 6,100 indirectly-held shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.02 on 2026-07-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, price, and post-transaction holdings under a 10b5-1 plan. It does not include new company fundamentals.
Market read
Traders may note the disclosed sale and reduced holdings, but the 10b5-1 structure makes it unlikely to drive a durable repricing by itself.
What to watch
The sale is indirect and under a pre-arranged plan, which reduces interpretability; without additional context (e.g., other insiders selling or new guidance), signal quality is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Oric Pharmaceuticals, Inc.
Ticker impact
Oric Pharmaceuticals director Heyman Richard A. sold 6,100 shares on 2026-07-24 at $12.0200 via a 10b5-1 plan, worth $73,322.
Likely minimal near-term impact; any reaction would be small and short-lived unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.
Market effects
No clear sector read-through; this is company-specific insider selling with no stated business change.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still coincide with investor skepticism, so traders may watch for follow-on selling volume.
Key entities
- issuerOric Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHeyman Richard A.
Director who sold shares under a pre-arranged 10b5-1 plan.